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The primary function of the blood coagulation cascade is to prevent blood loss after vessel injury. This cascade is ini-
tiated by the TF (tissue factor)/FVIIa (factor VIIa) complex. 
FXa (factor Xa) and thrombin are components of the so-called 
common pathway.1–3 Thrombin is the central protease of the 
blood coagulation cascade and has numerous roles, including 
cleavage of fibrinogen to fibrin and activation of platelets 
(Figure). Aberrant activation of the blood coagulation system 
can contribute to the pathology of various diseases. Formation 
of thrombi within blood vessels leads to ischemia and inflam-
mation. In addition, fibrin degradation products are released 
during the degradation of fibrin, that can enhance inflamma-
tion. For instance, the E1 fragment increases the recruitment 
of leukocytes to sites of injury by binding to VE-cadherin 
on endothelial cells and integrin αMβ2 on leukocytes.4 In 
addition, macrophage activation is enhanced by binding to 
fibrin(ogen) via αMβ2.5 Moreover, activated platelets can en-
hance inflammation by releasing inflammatory mediators and 
by promoting extravasation of leukocytes.6 Finally, FXa and 
thrombin activate a variety of cell types, including endothe-
lial cells, vascular smooth muscle cells, macrophages, fibro-
blasts, and cardiac myocytes, via PARs (protease-activated 
receptor; Figure). There are 4 members of the PAR family 
(PAR1–4), and they are ubiquitously expressed. These recep-
tors belong to the large family of G-protein–coupled receptors 
but are unique because they are activated by proteolytic cleav-
age that exposes a tethered ligand. Thrombin activates PAR1, 
PAR3, and PAR4, whereas FXa primarily activates PAR2.7–10 
Importantly, other proteases also activate PAR1 and PAR2. 
For example, APC (activated protein C) and matrix metal-
loproteases activate PAR1,11–13 whereas trypsins, tryptase, 
FVIIa, and matriptase activate PAR2.14–16 In addition, PAR1 
and PAR2 can form heterodimers17,18 Interestingly, human 
platelets express PAR1 and PAR4, whereas mouse platelets 
express a PAR3/PAR4 complex.19–21 This means that any phe-
notype observed in Par1−/− mice cannot be because of an at-
tenuation of platelet activation. Furthermore, there may be 
differences in PAR signaling in mice and humans.
A number of anticoagulants, such as vitamin K antagonists 
and various forms of heparins, are used to prevent and treat 
venous thrombosis and prevent stroke associated with atrial 
fibrillation.22 Direct oral anticoagulants (DOACs), which are 
also known as non-vitamin K antagonist oral anticoagulants, 
are a relatively new class of anticoagulants that specifically 
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Abstract—Activation of the blood coagulation cascade leads to fibrin deposition and platelet activation that are required for 
hemostasis. However, aberrant activation of coagulation can lead to thrombosis. Thrombi can cause tissue ischemia, and 
fibrin degradation products and activated platelets can enhance inflammation. In addition, coagulation proteases activate 
cells by cleavage of PARs (protease-activated receptors), including PAR1 and PAR2. Direct oral anticoagulants have 
recently been developed to specifically inhibit the coagulation proteases FXa (factor Xa) and thrombin. Administration 
of these inhibitors to wild-type mice can be used to determine the roles of FXa and thrombin in different inflammatory 
diseases. These results can be compared with the phenotypes of mice with deficiencies of either Par1 (F2r) or Par2 
(F2rl1). However, inhibition of coagulation proteases will have effects beyond reducing PAR signaling, and a deficiency 
of PARs will abolish signaling from all proteases that activate these receptors. We will summarize studies that examine 
the roles of coagulation proteases, particularly FXa and thrombin, and PARs in different mouse models of inflammatory 
disease. Targeting FXa and thrombin or PARs may reduce inflammatory diseases in humans.
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inhibit FXa and thrombin.23,24 There are several FXa inhibi-
tors (apixaban, betrixaban, edoxaban, and rivaroxaban) but 
only 1 approved thrombin inhibitor called dabigatran etexi-
late, which is a prodrug that is metabolized to dabigatran.24 
Various DOACs have been used to study the roles of FXa and 
thrombin in various mouse models of disease, but rivaroxaban 
and dabigatran are the most popular. As expected, therapeutic 
doses of these inhibitors reduce thrombosis in mice.25–27 We 
will not discuss studies that investigated the antithrombotic 
activities of these drugs. One would expect different effects 
of rivaroxaban versus dabigatran on PAR signaling. For in-
stance, inhibiting FXa would be expected to primarily inhibit 
PAR2 signaling, whereas inhibiting thrombin would primarily 
inhibit PAR1 signaling, as well as PAR3 and PAR4 signaling 
(Figure). Additionally, Par2−/− and Par1−/− mice can be used to 
compare and contrast the effects seen in wild-type mice with 
pharmacological inhibition of either FXa or thrombin, re-
spectively. However, inhibition of proteases will have effects 
beyond PAR signaling, and a Par deficiency will abolish 
signaling from multiple proteases. In addition, studies with 
Par1−/− or Par2−/− mice do not provide any information on 
the protease(s) that are activating the PARs in a given disease 
or the effector cells that are expressing the PARs. Recently, 
transgenic mouse lines containing floxed Par1 and Par2 genes 
have been generated (J. Palumbo, unpublished data, 2018; E. 
Camerer, unpublished data, 2018), and these mice are being 
used to determine the role of PAR1 and PAR2 in different cell 
types in multiple diseases. Similarly, transgenic mice have 
been made that express mutant forms of PAR1 and PAR2 
that cannot be activated by particular proteases. For instance, 
PAR1R41Q cannot be activated by either thrombin or APC, 
whereas PAR1R46Q cannot be activated by APC.28 Another 
mouse line was generated that expresses PAR2G37I that is re-
sistant to activation by FXa.29 These mice will be useful to 
determine the role of different proteases in the activation of 
PARs in various diseases.
In this review, we summarize the effects of inhibiting dif-
ferent coagulation proteases, particularly FXa and thrombin, 
in wild-type mice and compare these results with the pheno-
types of Par1- and Par2-deficient mice in various mouse mod-
els of inflammatory disease. We will not discuss studies on 
cancer because this topic has been reviewed previously.30–33
Doses of Rivaroxaban and Dabigatran Etexilate 
Used in Mouse Studies
The therapeutic dose of rivaroxaban used in humans is be-
tween 0.13 and 0.27 mg/kg (based on a patient weight of 75 
kg), which gives peak plasma concentrations of 122 to 250 
ng/mL.34,35 Dabigatran etexilate has a low bioavailability, and, 
therefore, it requires a high therapeutic dose in humans be-
tween 2 and 4 mg/kg, which gives peak plasma concentrations 
of 121.6 to 172.9 ng/mL (dose between 2.9 and 4.0 mg/kg).36–
38 When using DOACs in mice, one has to consider the bio-
logical differences between humans and mice, including the 
faster metabolism of mice, the shorter half-life in mice, and 
the fact that the drugs were developed to inhibit the human co-
agulation proteases.39 Therefore, higher doses of these drugs 
are needed for mice.
Rivaroxaban and dabigatran etexilate as well as other 
DOACs, such as edoxaban, are administrated to mice via ei-
ther chow, oral gavage, or intravenous injection (Tables 1 and 
2). Most studies report the dose in terms of milligrams per 
gram of chow. Only some studies report the plasma levels 
of the drug and present data from plasma-based functional 
assays that indicate the level of anticoagulation (Tables 1 and 
2). Plasma levels of rivaroxaban and dabigatran can be meas-
ured using an anti–FXa-based assay and chromatography 
mass spectrometry, respectively.40,41
There is a wide range of doses of rivaroxaban that have 
been used in mice (0.006–1.2 mg/g chow; Table 1). We 
found that a rivaroxaban dose of 1.2 mg per chow produced 
a plasma level of 150 to 260 ng/mL in apoE−/− mice fed a 
Western diet (40.5% fat and 0.25% cholesterol; J. Posma and 
H. Spronk, unpublished data, 2018). Rivaroxaban induces
a linear, concentration-dependent prolongation of the pro-
thrombin time, making it a suitable test to measure the level 
of anticoagulation with rivaroxaban.34 One study used 3 dif-
ferent doses of rivaroxaban (0.01, 0.2, and 0.4 mg/g chow) 
and found a significant increase in prothrombin time with 
the 2 higher doses.45 A smaller range of dabigatran etexilate 
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Figure.  Roles of coagulation proteases and downstream pathways in 
inflammatory diseases. Activation of the coagulation cascade leads to 
cleavage of fibrinogen into fibrin and platelet activation that can contribute 
to thrombosis. Platelet activation, and fibrin degradation products can also 
enhance inflammation. Additionally, coagulation proteases can activate 
cells via various PARs (protease-activated receptors) that can increase the 
expression of inflammatory mediators. FVIIa indicates factor VIIa; FXa, fac-
tor Xa; and TF, tissue factor.
doses have been used in different mouse studies (Table 2). 
Interestingly, the level of absorption of dabigatran etexi-
late is affected by the type of diet.46,48 The activated partial 
thromboplastin time correlates with the level of dabiga-
tran at therapeutic plasma levels and is used to monitor the 
anticoagulation of this DOAC. However, the activated par-
tial thromboplastin time loses sensitivity at supratherapeu-
tic levels of dabigatran (>200 ng/mL).54,55 Thrombin time is 
sensitive to the levels of dabigatran etexilate at plasma levels 
<60ng/mL, but no correlation is observed at higher levels.56 
Table 1. Effects of Rivaroxaban in Mouse Models of Inflammatory Disease
Animal Model Chow, mg/g
[Rivaroxaban] 
Plasma, ng/mL
PT, s; Control vs 
Rivaroxaban Major Findings Reference
apoE−/− 0.006 6.5 Inflammation↓, stability→ 42
apoE−/− 0.031 24.2 Inflammation↓, plaque stability↑ 42
apoE−/− WD 0.031 28.5 Inflammation↓, atherogenesis↓, plaque 
stability↑
43
apoE−/− WD 1.2 210 Inflammation↓, atherogenesis↓, plaque 
stability↑, plaque regression
Unpublished*
Ldlr−/− WD 1.2 Atherogenesis↓ Unpublished
MI I/R-O 0.54 340 Inflammation↓, ejection fraction↑ 44
MI I/R-O 1.2 790 Inflammation↓, ejection fraction↑, survival↑ 44
MI I/R-C 1.6 mg/kg 
bodyweight IV
Infarct size↓, ejection fraction↑ Unpublished
MI LAD 0.5 500 10→12 Ejection fraction↑, remodeling↓ 40
SCD 0.013 ND No change 45
SCD 0.2 75 14→22 45
SCD 0.4 190 14→28 Inflammation↓ 45
CVB3 0.5 Virus↓ Unpublished
IAV 0.5 Survival↑ Unpublished
apoE−/− indicates apolipoprotein E deficient; CVB3, coxsackievirus B3; I/R-C, ischemia reperfusion closed chest; I/R-O, ischemia-reperfusion 
open chest; IAV, influenza A virus; LAD, left anterior descending; Ldlr−/−, low-density lipoprotein receptor deficient; MI, myocardial infarction; ND, 
not determined; PT, prothrombin time; SCD, sickle cell disease; TAT, thrombin-antithrombin; and WD, Western diet.
*Thrombin generation assay lag time: 2.2→3.4 min.
Table 2. Effects of Dabigatran in Mouse Models of Inflammatory Disease
Animal Model Chow, mg/g
[Dabigatran] 
Plasma, ng/mL
aPTT (s) Control 
vs Dabigatran Major Findings Reference
apoE−/− WD 5.6 622 Atherogenesis↓, plaque stability↑ 46
apoE−/− WD 7.5 100–200 Atherogenesis↓, plaque stability↑ 47
apoE−/− WD 10 372 Atherogenesis↓ 48*
apoE−/− 10 Atherogenesis↓, plaque stability↑ 49
apoE−/−; Tmpro/pro; cuff WD 7.5 Inflammation↓, atherogenesis↓, 
plaque stability↑
50†
SCD 0.75 50 45
SCD 5 200 45
SCD 10 190 25→75 45‡
SCD 15 900 25→95 Spontaneous bleeding Unpublished
NAFLD HFD 10 Inflammation↓, hepatic fibrin↓, 
steatosis↓
51,52
CVB3 10 25→68 Myocarditis↑ 53
apoE−/− indicates apolipoprotein E deficient; aPTT, activated partial thromboplastin time; CVB3, coxsackievirus B3; HFD, high-fat diet; NAFLD, non-




One study evaluated 3 doses of dabigatran (5, 10, and 15 
mg/g chow) in mice and found that the 10- and 15-mg/g 
doses significantly increased the activated partial thrombo-
plastin time.45 Another study found that a dose of 10 mg/g of 
dabigatran etexilate increased the thrombin time from 30 to 
93 seconds.48 An oral dose of 100 mg/kg body weight of dab-
igatran etexilate did not cause any bleeding complication.57 
This study showed that dabigatran is rapidly cleared in mice 
with a half-life of 1.25 hours. However, sickle cell mice bled 
spontaneously when dabigatran etexilate was given by chow 
at a dose of 15 mg/g chow, and wild-type mice bled spon-
taneously when they received a dose of 500 mg/kg of body 
weight by oral gavage (E. Sparkenbaugh and R. Pawlinski, 
unpublished data, 2018).
Atherosclerosis
High levels of TF expression and procoagulant activity are 
present in human atherosclerotic plaques.58–60 TF expression 
has also been observed in a rabbit model of atherosclerosis.61 
In addition, levels of TF expression are increased with pro-
gression of human lesions.62
ApoE−/− and Ldlr−/− mice are the most common models 
used to study atherosclerosis in mice.63 Humans carry the ma-
jority of their lipoproteins in the LDL (low-density lipopro-
tein) subfraction, whereas mice transport their lipoproteins 
via high-density lipoprotein. Feeding apoE−/− and Ldlr−/− a 
Western diet, which is classically regarded as 42% fat and 
0.2% cholesterol, results in high levels of LDL that resembles 
distinct genetic disorders in humans (familial dysbetalipo-
proteinemia and hypercholesterolemia). However, mice fed 
a Western diet also have abnormally high chylomicrons and 
LDL compared with humans. ApoE−/− mice develop sponta-
neous atherosclerotic lesions on regular chow, but atheroscle-
rosis is markedly accelerated by feeding a Western diet.64,65 
In contrast, most studies with Ldlr−/− mice use a Western diet 
because there is limited atherosclerosis on regular chow with 
young mice. Atherosclerosis is normally measured in the aortic 
sinus, ascending aorta, and innominate artery. Addition of a 
cuff around the carotid artery creates vascular shear stress and 
vascular injury that accelerates atherosclerosis. Deletion of the 
apoE gene interferes with various processes, including mac-
rophage and adipose tissue biology, whereas deletion of the 
Ldlr gene primarily affects LDL clearance from the liver.66,67 
When interpreting mouse data, one also has to consider the 
differences between mice and humans, including differences 
in lesion distribution, medial layer size, and lipoprotein trans-
port.63,68 Both apoE−/− and Ldlr−/− mice fed a Western diet 
have a prothrombotic state, as measured by increased levels of 
plasma thrombin-antithrombin complex.69,70
Effect of Deficiencies of Procoagulant or 
Anticoagulant Proteins on Atherosclerosis in Mice
Components of the coagulation system have been implicated 
in the development of atherosclerosis.69 Increased athero-
sclerotic lesion development was observed in apoE−/− mice 
expressing the hypercoagulable Factor V Leiden variant, 
which is likely because of an increased capacity for thrombin 
generation.70 Similarly, a 50% reduction in TF pathway 
inhibitor—the endogenous inhibitor of TF—increased the 
development of lesions in apoE−/− mice fed regular chow.71 
Conversely, a 50% reduction of TF did not alter atheroscle-
rotic lesion development in apoE−/− mice fed regular chow.72 
Similarly, no difference in atherosclerotic lesion development 
was observed in Ldlr−/− mice reconstituted with bone marrow 
expressing low levels of TF on a Western diet.72
Genetic studies have investigated the role of thrombin 
on the development of atherosclerosis. Interestingly, apoE−/− 
mice with 50% levels of prothrombin had reduced lesion 
burden on regular chow.50 The role for fibrinogen—the major 
physiological substrate of thrombin—in atherosclerosis is 
model dependent. In addition, it should be noted that fib−/− 
mice are difficult to breed. In the apoE−/− model, fibrinogen 
deficiency did not alter atherosclerotic lesion development 
in mice on normal chow.73 However, in a transgenic mouse 
model expressing human apo(a), deletion of fibrinogen signif-
icantly reduced lesion development in mice fed a Western diet 
because of reduced binding of apo(a) to fibrin(ogen) in the 
vessel wall.74 Finally, fibrinogen deficiency increased plaque 
development in Ldlr−/− mice with a deficiency in apobec1.75 
Taken together, these genetic studies suggest that thrombin 
contributes to atherosclerosis in mouse models.
Effect of Thrombin Inhibition on Atherosclerosis  
in Mice
The first study on the effect of the orally available thrombin 
inhibitor melagatran was performed in 2006.76 Melagatran 
decreased progression of advanced lesions in apoE−/− mice 
on chow.76 In addition, melagatran decreased inflammation 
and macrophages in the lesion and increased collagen and 
fibrous cap thickness, which is suggestive of a stable plaque 
phenotype. Similarly, dabigatran etexilate reduced ather-
osclerosis in apoE−/− mice on chow.49 Moreover, 3 studies 
demonstrated that dabigatran etexilate (5.6–10 mg/g chow) 
reduced atherosclerosis in apoE−/− mice fed a Western 
diet.46–48 These studies also showed that thrombin inhibi-
tion reduced inflammation, macrophage accumulation, and 
necrotic core volume while increasing fibrous cap thickness 
and improving endothelial function. In the cuff model, dabi-
gatran etexilate reduced atherosclerosis in Western diet-fed 
apoE−/− mice expressing a mutant version of thrombomodulin 
with reduced anticoagulant activity.50 In contrast, the thrombin 
inhibitor bivalirudin did not attenuate atherosclerosis.77 
However, bivalirudin has a short half-life and was adminis-
tered daily via subcutaneous injection. Taken together, the 
majority of studies demonstrated that inhibition of thrombin 
decreased atherosclerosis and inflammatory mediators, such 
as IL-6 (interleukin-6), MCP-1 (monocyte chemoattractant 
protein 1), IFN-γ (interferon gamma), and TNF-α (tumor ne-
crosis factor-α), in apoE−/− mice.
Effect of FXa Inhibition on Atherosclerosis in Mice
Low-dose rivaroxaban attenuated the development of ather-
osclerosis and inflammation in the aorta of 8-week-old male 
apoE−/− mice fed a Western diet for 20 weeks.78 Interestingly, 
low-dose rivaroxaban (0.006 and 0.031 mg/g chow) did not 
induce plaque regression in female apoE−/− mice fed regular 
chow for 26 weeks and then given rivaroxaban for an addi-
tional 26 weeks.42,78 However, both doses of rivaroxaban 
reduced the expression of inflammatory mediators, such 
as TNF-α and IL-6.42 Additionally, the 0.031 mg/g dose of 
rivaroxaban stabilized the plaque phenotype as reflected by 
a thicker fibrous cap, smaller necrotic cores, and more col-
lagen.42 We found that high-dose rivaroxaban (1.2 mg/g diet) 
reduced the development of atherosclerosis in 8-week-old 
female Ldlr−/− mice fed a Western diet for 14 weeks in the 
cuff model (J. Posma and H. Spronk, unpublished data, 2018). 
Additionally, we examined the effect a high-dose rivaroxaban 
(1.2 mg/g chow) on preexisting plaques by feeding female 
apoE−/− mice Western diet for 14 weeks and then administer-
ing rivaroxaban for 6 weeks in the cuff model. Rivaroxaban 
promoted regression of preexisting plaques (J. Posma and H. 
Spronk, unpublished data, 2018). These differences are likely 
because of the use of a different dose of rivaroxaban (1.2 
versus 0.03 mg/g chow) with the higher dose more typical for 
studies with rivaroxaban.
Effect of Par1 Deficiency or Par1 
Inhibition on Atherosclerosis in Mice
PAR1 expression is increased in human and mouse atheroscle-
rotic lesions suggesting that it may play a role in atheroscle-
rosis.79 There are several studies that have investigated the role 
of PAR1 in atherosclerosis in the apoE−/− and Ldlr−/− models 
(Table 3). However, the data are inconsistent between the 2 
models. In the apoE−/− mouse model with Western diet Par1 de-
ficiency reduced atherosclerosis, whereas Par1 deficiency had 
no effect in the Ldlr−/− model fed Western diet.79–81 Inhibition 
of PAR1 with the cell penetrating PAR1 pepducin PZ-128 also 
reduced atherosclerosis, macrophage content of plaques, and 
inflammation in apoE−/− mice fed a Western diet.77 However, 
one must be cautious with the interpretation of this data be-
cause PZ-128 also inhibits signaling from a PAR1/PAR2 het-
erodimer.82 In vitro studies indicated that the thrombin-PAR1 
pathway inhibits cholesterol efflux in macrophages and vas-
cular smooth muscle cells, and contributes to leukocyte migra-
tion into lesions.80 These results suggest that PAR1 plays a role 
in the apoE−/− model but not in the Ldlr−/− model. Future studies 
should directly compare the phenotypes of apoE−/− mice treated 
with dabigatran etexilate and apoE−/− lacking Par1.
Thrombin also activates PAR4 and is the main thrombin 
receptor on mouse platelets.19 Platelets have been shown to 
contribute to atherosclerosis in mice.88 An early study found 
that Par4 deficiency did not affect atherosclerosis in apoE−/− 
mice fed a Western diet.89 In contrast, we observed a signifi-
cant reduction in atherosclerosis in male Ldlr−/− mice lacking 
Par4 fed a Western diet for 12 weeks (A.P. Owens 3rd and 
N. Mackman, unpublished data, 2018). This suggests that the
contribution of the thrombin/PAR4 pathway is relatively mild
and can only be detected in the Ldlr−/− model.
Effect of PAR2 Deficiency on Atherosclerosis  
in Mice
PAR2 expression is increased in human atherosclerotic 
plaques suggesting that it may contribute to plaque pro-
gression.79 Several studies have determined the effect of 
Par2 deficiency on atherosclerosis in mice (Table 4). Par 
2 deficiency was associated with reduced atherosclerosis, 
reduced inflammation, and increased plaque stability in 
apoE−/− mice fed a Western diet.90 This phenotype was 
confirmed and extended by a later study.43 Bone marrow 
transplantation experiments indicated that Par2 on hema-
topoietic cells but not nonhematopoietic cells drove ath-
erosclerosis.43 Furthermore, in vitro studies showed that 
activation of PAR2 on macrophages increased inflamma-
tion. Additionally, the PAR2 pepducin inhibitor PZ-235 
showed no effects on lesion development in apoE−/− mice 
fed a Western diet.77 We found that a deficiency of Par2 also 
attenuated atherosclerosis in Ldlr−/− mice fed a Western 
diet.79 Mice lacking Par2 had decreased expression of 
Table 3. Effects of Par1 Deficiency in Mouse Models of Inflammatory Disease
Animal Model Major Findings in Par1−/− Reference
apoE−/− WD Atherogenesis↓ 80
Ldlr−/− WD Atherogenesis↔ 79
I/R-O Remodeling↓ 83
SCD 45
NAFLD Inflammation↓, steatosis↓ 84
NAFLD Inflammation↓, steatosis↓ 51
NAFLD Inflammation↓ 85
CVB3 Infection↑, myocarditis↑ 53
IAV Infection↑ 53




apoE−/− indicates apolipoprotein E deficient; CVB3, coxsackievirus B3; IAV, 
influenza A virus; I/R-O, ischemia-reperfusion open chest; NAFLD, non-alcoholic 
fatty liver disease; PF, pulmonary fibrosis; SCD, sickle cell disease; and WD, 
Western diet.
Table 4. Effects of Par2 Deficiency in Mouse Models of Inflammatory Disease
Animal Model Major Findings in Par2−/− References
apoE−/− WD Inflammation↓, atherogenesis↓ 90
apoE−/− WD Inflammation↓, atherogenesis↓ 43
Ldlr−/− WD Inflammation↓, atherogenesis↓ 79
I/R-O Infarct size↓, inflammation↓ 91
LAD Ejection fraction↑, remodeling↓ 40
SCD Inflammation↓ 45




Diabetic nephropathy Fibrosis↓, inflammation↓ 94
CVB3 Infection↓, myocarditis↓ 95
IAV Survival↑ 96
IAV Survival↓ 97
apoE−/− indicates apolipoprotein E deficient; CVB3, coxsackievirus B3; I/R-O, 
ischemia-reperfusion open chest; IAV, influenza A virus; LAD, left anterior 
descending; Ldlr−/−, low-density lipoprotein receptor deficient; NAFLD, non-
alcoholic fatty liver disease; SCD, sickle cell disease; and WD, Western diet.
the chemokines CCL2 and CXCL1 in the circulation.79 
However, in contrast to the studies with the apoE−/− mice, 
bone marrow transplantation experiments indicated that 
Par2 on nonhematopoietic cells but not hematopoietic cells 
drove atherosclerosis in this model. In vitro studies indi-
cated that activation of PAR2 on vascular smooth muscle 
cells induced Ccl2 and Cxcl1 expression and enhanced 
monocyte migration.79 It is surprising that there are cell 
type differences in the role of PAR2 in the apoE−/− and 
Ldlr−/− mice. Additional studies are needed to compare the 
phenotypes of wild-type mice treated with rivaroxaban and 
Par2−/− mice in the 2 models.
Myocardial Infarction
Myocardial infarction is a leading cause of morbidity and mor-
tality. The most commonly used models of myocardial infarc-
tion in mice are either permanent ligation of the left anterior 
descending (LAD) artery or temporary ligation of the LAD fol-
lowed by reperfusion (ischemia-reperfusion model [I/R]).40,98 
I/R can be either an open-chest model (I/R-O) similar to LAD, 
where the opening of the chest precedes I/R on the same day,98 
or in a closed-chest model where the ligature is placed around 
the LAD without tying and mice allowed to recover for 5 to 7 
days before ligation (I/R-C).99 In the I/R-O model, the surgery 
contributes to the inflammatory response, whereas in the I/R-C 
model, most of the surgical inflammation has resolved at days 
5 to 7.99 The I/R models provide information on the role of 
different pathways involved in reperfusion injury.
Effect of Inhibition of Coagulation on Myocardial  
Infarction in Mice
We found that inhibiting the TF/FVIIa complex in mice with 
active site-inhibited FVIIa reduced infarct size in an I/R-C 
model that consisted of 60 minutes of ischemia and 2 hours 
of reperfusion.100 This was associated with reduced leukocyte 
infiltration and decreased gene expression of inflammatory 
mediators, such as IL-6, intercellular adhesion molecule-1, 
and IL-1β.100 Similarly, the thrombin inhibitor hirudin also 
reduced infarct size in the I/R-O model that consisted of 30 
minutes of ischemia and 2 hours of reperfusion.83 We deter-
mined the effect of rivaroxaban on infarct size in an I/R-C 
model by administering 2 doses of rivaroxaban via intrave-
nous injection (1.6 mg/kg) 15 minutes after ischemia and 5 
minutes after reperfusion. Rivaroxaban significantly reduced 
infarct size after 24 hours (J. Posma and H. Spronk, unpub-
lished data, 2018).
In the LAD permanent ligation model, administration 
of rivaroxaban (0.5 mg/g chow) immediately after cardiac 
injury did not alter infarct size but reduced remodeling of 
the heart and preserved ejection fraction after 3 days and 
beyond compared with the placebo group.40 Interestingly, 
no protection was observed when rivaroxaban treatment 
was started 3 days post-ligation. This suggests that FXa 
inhibition affects the acute inflammatory phase in this 
model. However, rivaroxaban treatment did not alter in-
flammatory mediators 2 days after ligation.40 In this study, 
an open-chest model was used that promotes inflamma-
tion, which might have masked the effects of FXa inhibi-
tion on inflammation.
These studies indicate that coagulation proteases con-
tribute to inflammation and infarct size after cardiac I/R injury. 
The protective effects seen with inhibition of coagulation after 
cardiac injury may be because of a combination of reduced 
fibrin deposition, activation of PARs and other downstream 
effects, such as generation of fibrin degradation products and 
platelet activation.
Effect of Par1 Deficiency on Myocardial Infarction  
in Mice
We found that Par1 deficiency did not affect infarct size but 
reduced remodeling 2 weeks post-infarction in an I/R-O model 
(Table 3).83 The lack of effect of PAR1 on infarct size may be 
because it mediates both pathological and protective pathways 
via APC. Indeed, exogenous APC was shown to reduce infarct 
size after I/R injury, and this effect was abolished in Par1−/− 
mice.101,102 As stated above, Par1 deficiency does not affect 
platelet activation in mice. However, Par4 deficiency reduced 
infarct size in an I/R-O model.103 These studies suggest that 
some of the beneficial effects of thrombin inhibition might be 
because of a reduction in PAR4 signaling.
Effect of Par2 Deficiency on Myocardial Infarction  
in Mice
We found that Par2 deficiency attenuated infarct size in 
an I/R-O model consisting of 30 minutes of ischemia and 
2 hours of reperfusion (Table 4).91 In addition, hearts of 
Par2−/− mice had reduced levels of inflammatory media-
tors, such as IL-1β and TNF-α, and decreased remodeling 
compared with hearts from wild-type mice.91 In the LAD 
permanent ligation model, Par2−/− mice had reduced remod-
eling and preserved ejection fraction after 28 days.104 This 
result is similar to the protective effects of rivaroxaban in the 
wild-type mice.40 Indeed, rivaroxaban did not provide any 
protection to Par2−/− mice in the LAD permanent ligation 
model.40 However, one must be cautious in interpreting these 
results because FXa and PAR2 may play roles in parallel 
pathways that contribute to cardiac remodeling after myo-
cardial infarction. For instance, administration of rivaroxa-
ban would reduce levels of the fibrin degradation fragment 
E1, which has been shown to exacerbate I/R injury4 (Figure). 
Additionally, activation of PAR2 by other protease would be 
abolished in Par2−/− mice.
Diet-Induced Obesity
Obesity is a global healthcare crisis with an estimated 34% 
of adults in the United States classified as obese.105 Obesity 
leads to chronic activation of the coagulation cascade and is 
a risk factor for the development of metabolic syndrome.84,106 
High levels of TF are expressed in adipose tissue, and there is 
abundant fibrin deposition in adipose tissue.51,107,108 The role of 
the coagulation cascade and PARs in diet-induced obesity has 
been studied using different mouse models that are associated 
with body weight gain, inflammation, macrophage recruit-
ment to the adipose tissue, and insulin resistance.
Two studies from the Samad group found that Par2−/− mice 
and mice expressing a mutant form of TF that lacks the cy-
toplasmic domain had reduced weight gain in a diet-induced 
obesity model.92,93 It was proposed that hematopoietic cell 
TF-PAR2 signaling increases adipose inflammation, hepatic 
inflammation, hepatic macrophage recruitment, and steatosis, 
whereas nonhematopoietic cell TF-FVIIa-PAR2 signaling 
drives obesity.
We found that mice expressing low levels of TF exhibited 
significantly less body weight gain when fed a high-fat diet 
(HFD; 45% kcal fat) for 16 weeks compared with controls (Y. 
Hisada and N. Mackman, unpublished data, 2018). Notably, 
adipocyte size was increased in epididymal and subcutaneous 
fat in wild-type controls but not in low TF mice (Y. Hisada and 
N. Mackman, unpublished data, 2018). Similarly, low levels
of TF expression in hematopoietic cells were also associated
with significantly less body weight gain in Ldlr−/− mice fed
a Western diet compared with controls.106 Administration of
dabigatran etexilate to C57BL/6J mice reduced body weight
gain when fed an HFD.51,52 Dabigatran also suppressed the
progression of sequelae in mice with establish obesity.51 In
contrast, a deficiency of Par1 did not affect diet-induced
body weight gain.51,84 This initiated a search for the effector
molecule(s) downstream of thrombin that drove obesity. One
obvious candidate was fibrinogen. A previous study found
that a sequence in the fibrinogen γ-chain (390–396) binds to
macrophages via αMβ2 and that mutation of this sequence
abolished binding.109 Strikingly, mice expressing this mutant
fibrinogen Fibγ390–396A were protected from diet-induced body
weight gain in a similar way to thrombin-inhibited wild-type
mice.51 Similar to the results we observed with low TF mice,
the size of adipocytes was not increased in Fibγ390–396A mice
fed an HFD.51 In addition, Fibγ390–396A mice had reduced num-
bers of macrophages in the adipose tissue.51 These results
suggest that thrombin drives diet-induced obesity via fibrin-
dependent inflammation in the adipose.
Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease is the liver manifestation of 
metabolic syndrome and is estimated to affect ≈25% of the 
Western population.110 Mice fed a Western diet develop he-
patic inflammation and fatty livers that is mainly because of 
the accumulation of triglycerides. This is referred to as stea-
tosis. We found that low TF fed a Western diet for 16 weeks 
did not develop steatosis (Y. Hisada and N. Mackman, unpub-
lished data, 2018). Similarly, low levels of TF expression in 
hematopoietic cells reduced hepatic steatosis in Ldlr−/− mice 
fed a Western diet.84 Par1 deficiency also reduced hepatic in-
flammation and steatosis in C57BL/6J mice fed a Western diet 
for 3 months.84 Finally, Fibγ390–396A mice had reduced hepatic 
inflammation and steatosis when fed a Western diet compared 
with controls.51 These results indicate that TF-thrombin-PAR1 
and TF-thrombin-fibrin pathways contribute to hepatic in-
flammation and steatosis in mice fed a Western diet.
Diabetic Nephropathy
Diabetic nephropathy is the most common cause of end-
stage renal disease in the United States.111 In a mouse model 
of diabetic nephropathy, FXa inhibition by edoxaban atten-
uated progression of the disease.94 This was associated with 
decreased expression of proinflammatory genes, such as 
TNF-α, and profibrotic genes, such as ΤGF-β. Interestingly, 
Par2 deficiency gave a similar phenotype, and edoxaban did 
not provide any additional protection to Par2−/− mice.94 The 
authors speculated that targeting FXa or PAR2 may reduce 
diabetic nephropathy in humans.
Sickle Cell Disease
A substitution of glutamic acid in normal hemoglobin for 
valine causes sickle cell disease. The mutant hemoglobin 
polymerizes and aggregates of hemoglobin tetramers leads to 
the formation of sickle red blood cells. Patients with sickle 
cell disease exhibit vaso-occlusion within postcapillary 
venules and have systemic inflammation and activation of co-
agulation.112 The 2 most common mouse models of sickle cell 
disease (Berkley [BERK] and Townes) have the mouse he-
moglobin genes replaced with their human counterparts.113,114 
BERK and Townes mice have severe anemia, systemic inflam-
mation, and activation of coagulation.115
The role of the clotting cascade in sickle cell mice has 
been analyzed using genetic and pharmacological approaches. 
Inhibition of TF reduced both coagulation and the inflam-
matory mediator IL-6 in both BERK and Townes mice.115 
Moreover, reducing TF expression in nonhematopoietic cells 
to ≈1% in BERK mice reduced plasma IL-6, cardiac hyper-
trophy, and infiltration of neutrophils into the lungs but not 
activation of coagulation.116 Deletion of TF in endothelial cells 
also reduced plasma IL-6 but not activation of coagulation.45 
Similarly, reducing circulating prothrombin to ≈10% of wild-
type levels using an antisense oligonucleotide decreased early 
mortality in BERK mice.117 In addition, a genetic reduction 
of prothrombin to ≈10% of wild-type levels in BERK mice 
reduced inflammation, endothelial dysfunction, and end-
organ damage in the kidney, liver, and lung.117
Interestingly, short-term FXa inhibition with rivaroxa-
ban, but not short-term thrombin inhibition with dabigatran, 
significantly reduced IL-6 plasma levels in sickle cell mice.45 
Similarly, Par2−/− mice but not Par1−/− mice with sickle cell 
bone marrow had reduced levels of plasma IL-6.45 These 
results indicate that TF, FXa, and thrombin contribute to the 
activation of coagulation in sickle cell mice. In contrast, in-
flammation and end-organ dysfunction are more complex 
and seem to be driven by multiple pathways that include 
endothelial cell TF expression that activates PAR2 and also 
thrombin-dependent pathways. The different phenotypes 
observed in sickle cell mice may be because of the use of ge-
netic versus pharmacological approaches and short- versus 
long-term studies.
Viral Infections
The blood coagulation cascade is activated in response to viral 
infection and can lead to disseminated intravascular coagula-
tion.118 Inhibition of the TF/FVIIa complex reduced inflamma-
tion and mortality in a primate model of Ebola hemorrhagic 
fever.119 The roles of PAR1 and PAR2 in mouse models of 
viral infections are controversial.118
Coxsackievirus B3
We found that inhibition of either TF with an antibody or 
thrombin with dabigatran etexilate increased viral load and 
myocarditis after infection of mice with coxsackievirus B3 
(CVB3).53 Similarly, Par1−/− mice exhibited increased CVB3-
induced myocarditis (Table 3). TLR3 (Toll-like receptor 3) is 
one of the main receptors in the innate immune system that 
detects single-stranded RNA viruses, such as CVB3. TLR3 
can be activated by the double-stranded RNA mimetic poly 
I:C. Importantly, we found that activation of PAR1 enhanced 
poly I:C induction of IFN-β expression in murine cardiac 
fibroblasts, suggesting that PAR1 contributes to the innate 
immune response to single-stranded RNA viral infection.53 
In complete contrast to the results with Par1−/− mice, Par2−/− 
mice were protected against CVB3-induced myocarditis.95 
We also found that administration of rivaroxaban (0.5 mg/g 
chow) to wild-type mice decreased CVB3-induced myo-
carditis (S. Antoniak and N. Mackman, unpublished data, 
2018). Interestingly, murine cardiac fibroblasts lacking 
PAR2 had higher levels of IFN-β expression after stimula-
tion with poly I:C compared with wild-type cells, suggesting 
that PAR2 negatively regulates TLR3-dependent expression 
of IFN-β.95 Similarly, PAR2 inhibited TLR3-dependent ex-
pression of IFN-β in human epithelial cells.96 These studies 
suggest that TLR3-dependent activation of antiviral path-
ways is positively and negatively regulated by PAR1 and 
PAR2, respectively.
Influenza A Virus
Influenza A virus (IAV) is a single-stranded RNA virus. 
Khoufache et al86 found that Par1 deficiency decreased in-
flammation and increased survival of mice infected with a 
mouse adapted H1N1 strain of IAV (Table 3). In contrast, 
we found that Par1−/− mice exhibited a decrease in the innate 
immune response and increase in virus genomes after IAV 
infection.53 We have also observed increased mortality in 
Par1−/− mice compared with wild-type controls after IAV 
infection (S. Antoniak and N. Mackman, unpublished data, 
2018). These variable results may be because of the use of a 
different dose of virus. Similarly, the results with Par2−/− are 
not consistent. Khoufache et al97 observed that Par2−/− mice 
had increased inflammation and decreased survival after IAV 
infection. In contrast, the Vogel group found that Par2−/− 
mice exhibited increased survival compared with controls 
after IAV infection.96 Similarly, administration of rivaroxa-
ban (0.5 mg/g chow) to wild-type mice increased survival 
after IAV infection compared with controls (S. Antoniak and 
N. Mackman, unpublished data, 2018). Further studies are
needed to determine the roles of coagulation proteases and
PARs in IAV infection.
Other Viruses
PAR1 inhibition protected mice against respiratory syncytial 
virus and human metapneumovirus infection.120 Similarly, 
thrombin inhibition with argatroban reduced the pathogenicity 
of the infection with no additional effect to PAR1 inhibition. 
In vitro studies with human A549 cells showed that PAR1 in-
hibition reduced the replication of respiratory syncytial virus 
and human metapneumovirus infection.120 Further studies are 
needed to determine the roles of coagulation proteases and 
PARs in different viral infections.
Sepsis/Endotoxemia
Sepsis is induced by a systemic infection and activates the 
coagulation system. Endotoxemia is related to sepsis and is 
caused by endotoxins, most commonly bacterial lipopolysac-
charide, in the blood. Lipopolysaccharide induces TF expres-
sion in monocytes.121 Administration of lipopolysaccharide 
to mice leads to a rapid activation of coagulation. We found 
that mice expressing low levels of TF had less activation of 
coagulation and prolonged survival compared with controls 
in an endotoxemia model.122 In a subsequent publication, we 
demonstrated endotoxemia-induced activation of coagulation 
was initiated by both hematopoietic and nonhematopoietic 
sources of TF.123 Furthermore, inhibition of thrombin with 
hirudin prolonged survival but did not reduce inflammation. 
We also found that Par1- and Par2-deficient mice were not 
protected against endotoxemia.122 An independent study also 
showed that a deficiency of Par1, Par2, or Par4 did not affect 
inflammation or survival in an endotoxemia model that used 
different doses of lipopolysaccharide and both sexes.124 In 
contrast to these 2 studies, 1 study reported protection of Par1-
deficient mice in an endotoxemia model.125 More recently, it 
was shown that mice expressing PAR1R41Q that cannot be ac-
tivated by thrombin were not protected in an E coli-induced 
pneumonia model.28 These studies indicate a role for TF and 
thrombin in the activation of coagulation in endotoxemia, but 
the role of PARs in the inflammatory response in this model 
is controversial.
Idiopathic Pulmonary Fibrosis
The coagulation cascade plays a critical role in hemostasis 
in the lung but also contributes to fibroproliferative lung dis-
eases, such as idiopathic pulmonary fibrosis. The ACE-IPF 
trial (Antioagulant Effectiveness in Idiopathic Fibrosis) inves-
tigated the effect of the anticoagulant warfarin in idiopathic 
pulmonary fibrosis but was stopped early because of excess 
risk of mortality.126 Bleomycin induces lung injury and fibrosis 
in mice and is an established model of human pulmonary fi-
brosis. We found that bleomycin increased TF expression in 
the lungs of mice.127 One study showed that administration 
of an FXa inhibitor ZK80734 to mice reduced bleomycin-
induced lung injury in mice.128 However, it is notable that 3 
of 6 mice that received saline and ZK80734 and 3 of 9 mice 
that received bleomycin and ZK80734 were euthanized be-
cause of intraperitoneal hemorrhage after administration of 
the drug. PAR1 is highly expressed in cells associated with 
fibrotic foci in idiopathic pulmonary fibrosis suggesting that 
it may contribute to fibrosis.129 Indeed, Par1−/− mice were pro-
tected from bleomycin-induced lung inflammation.87 In vitro 
studies showed that FXa activated PAR1 on human adult lung 
fibroblasts.128 PAR1 signaling leads to activation of TGF-β1, 
which is a key fibrotic mediator in many fibrotic conditions.
Conclusions
Activation of the blood coagulation leads to the generation 
of multiple coagulation proteases, fibrin deposition, proin-
flammatory fibrin degradation products, platelet activation, 
and PAR signaling (Figure). In atherosclerosis, inhibition 
of either FXa or thrombin reduces inflammation and lesion 
development. Similarly, a deficiency of Par2 reduces inflam-
mation and atherosclerosis, but PAR2 seems to play differ-
ent roles in the apoE−/− and Ldlr−/− models. Par1 deficiency 
reduces atherosclerosis in the apoE−/− model, and this may be 
because of reduced cholesterol influx and monocyte migration 
into lesions. However, Par1 deficiency had no effect in athero-
sclerosis in the Ldlr−/− model. In cardiac I/R injury, inhibition 
of either TF/FVIIa, FXa, or thrombin reduces inflammation 
and infarct size. Similarly, Par2−/− mice but not Par1−/− mice 
had reduced infarcts compared with controls. In diet-induced 
obesity mouse models, the TF/FVIIa-thrombin-fibrin pathway 
and PAR2-dependent pathways drive inflammation in adi-
pose tissue. In a mouse model of sickle cell disease, the TF/
FVIIa-FXa-PAR2 and TF-thrombin-PAR1 pathways drive 
inflammation and end-organ damage. The roles of PARs in 
viral infections are controversial. TLR3-dependent antiviral 
responses seem to be positively and negatively regulated by 
PAR1 and PAR2, respectively.
Further studies are needed with mice that express either 
mutant forms of the PARs or with cell type-specific deletion 
of PARs to elucidate how coagulation protease-PAR pathways 
contribute to different diseases.
Acknowledgments
We thank Drs Heitmeier, Luyendyk, Pawlinski, and Van Ryn for help-
ful comments.
Sources of Funding
This work was supported by funds from the John C. Parker Endowed 
Professorship, a grant from the National Institutes of Health 
(HL119523), and a grant from the Dutch Heart Foundation (Young 
Talent Program, CVON 2014-09).
Disclosures
N. Mackman is a consultant for Bayer. H. M. Spronk is a consultant
for Bayer and has a research grant from Bayer.
References
1. Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation
system as a molecular machine. Bioessays. 2003;25:1220–1228. doi:
10.1002/bies.10360
2. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood
coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 
2007;27:1687–1693. doi: 10.1161/ATVBAHA.107.141911
3. Monroe DM, Hoffman M. What does it take to make the perfect clot?
Arterioscler Thromb Vasc Biol. 2006;26:41–48. doi: 10.1161/01.ATV.
0000193624.28251.83
4. Petzelbauer P, Zacharowski PA, Miyazaki Y, Friedl P, Wickenhauser G,
Castellino FJ, Gröger M, Wolff K, Zacharowski K. The fibrin-derived pep-
tide Bbeta15-42 protects the myocardium against ischemia-reperfusion
injury. Nat Med. 2005;11:298–304. doi: 10.1038/nm1198
5. Flick MJ, Du X, Witte DP, Jirousková M, Soloviev DA, Busuttil SJ, Plow 
EF, Degen JL. Leukocyte engagement of fibrin(ogen) via the integrin re-
ceptor alphaMbeta2/Mac-1 is critical for host inflammatory response in
vivo. J Clin Invest. 2004;113:1596–1606. doi: 10.1172/JCI20741
6. Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating plate-
lets as mediators of immunity, inflammation, and thrombosis. Circ Res. 
2018;122:337–351. doi: 10.1161/CIRCRESAHA.117.310795
7. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent 
activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad 
Sci USA. 2000;97:5255–5260.
8. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis
and vascular biology. J Thromb Haemost. 2005;3:1800–1814. doi:
10.1111/j.1538-7836.2005.01377.x
9. Riewald M, Ruf W. Mechanistic coupling of protease signaling and
initiation of coagulation by tissue factor. Proc Natl Acad Sci USA. 
2001;98:7742–7747. doi: 10.1073/pnas.141126698
 10. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling.
Arterioscler Thromb Vasc Biol. 2005;25:47–56. doi: 10.1161/01.ATV. 
0000151624.45775.13
 11. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A.
PAR1 is a matrix metalloprotease-1 receptor that promotes invasion
and tumorigenesis of breast cancer cells. Cell. 2005;120:303–313. doi:
10.1016/j.cell.2004.12.018
 12. Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 ac-
tivation. Blood. 2013;121:431–439. doi: 10.1182/blood-2012-09-355958
 13. Sebastiano M, Momi S, Falcinelli E, Bury L, Hoylaerts MF, Gresele P.
A novel mechanism regulating human platelet activation by MMP-
2-mediated PAR1 biased signaling. Blood. 2017;129:883–895. doi:
10.1182/blood-2016-06-724245
 14. Corvera CU, Déry O, McConalogue K, Böhm SK, Khitin LM, Caughey
GH, Payan DG, Bunnett NW. Mast cell tryptase regulates rat co-
lonic myocytes through proteinase-activated receptor 2. J Clin Invest. 
1997;100:1383–1393. doi: 10.1172/JCI119658
 15. Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skåregärde A, Gedda K,
Peterson A, Chapman K, Hollenberg MD, Vergnolle N, Bunnett NW.
Trypsin IV or mesotrypsin and p23 cleave protease-activated recep-
tors 1 and 2 to induce inflammation and hyperalgesia. J Biol Chem. 
2007;282:26089–26100. doi: 10.1074/jbc.M703840200
 16. Le Gall SM, Szabo R, Lee M, Kirchhofer D, Craik CS, Bugge TH, Camerer 
E. Matriptase activation connects tissue factor-dependent coagulation in-
itiation to epithelial proteolysis and signaling. Blood. 2016;127:3260–
3269. doi: 10.1182/blood-2015-11-683110
 17. O’Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ,
Woulfe DS, Brass LF. Thrombin responses in human endothelial cells. 
Contributions from receptors other than PAR1 include the transactivation of 
PAR2 by thrombin-cleaved PAR1. J Biol Chem. 2000;275:13502–13509.
 18. McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman
N. Protease-activated receptors mediate crosstalk between coagu-
lation and fibrinolysis. Blood. 2010;116:5037–5044. doi: 10.1182/ 
blood-2010-06-293126
 19. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ,
Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 
2000;404:609–613. doi: 10.1038/35007085
 20. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a func-
tional thrombin receptor reveals a novel proteolytic mechanism of receptor 
activation. Cell. 1991;64:1057–1068.
 21. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR.
Protease-activated receptors 1 and 4 mediate activation of human platelets 
by thrombin. J Clin Invest. 1999;103:879–887. doi: 10.1172/JCI6042
 22. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber 
SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR.
Antithrombotic therapy for VTE disease: antithrombotic therapy and pre-
vention of thrombosis, 9th ed: American College of Chest Physicians evi-
dence-based clinical practice guidelines. Chest. 2012;141:e419S–e496S.
 23. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagu-
lants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 
2015;35:1056–1065. doi: 10.1161/ATVBAHA.115.303397
 24. Weitz JI, Harenberg J. New developments in anticoagulants: past,
present and future. Thromb Haemost. 2017;117:1283–1288. doi:
10.1160/TH16-10-0807
 25. Wagner NM, Dressel T, Schäfer K, Konstantinides S. Effect of the fac-
tor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and
apolipoprotein E-deficient mice. Thromb Res. 2012;130:793–798. doi:
10.1016/j.thromres.2012.01.002
 26. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y, Ohsaka A. Rivaroxaban 
attenuates leukocyte adhesion in the microvasculature and thrombus
formation in an experimental mouse model of type 2 diabetes mellitus.
Thromb Res. 2014;133:276–280. doi: 10.1016/j.thromres.2013.11.013
 27. Shaya SA, Saldanha LJ, Vaezzadeh N, Zhou J, Ni R, Gross PL. Comparison 
of the effect of dabigatran and dalteparin on thrombus stability in a murine 
model of venous thromboembolism. J Thromb Haemost. 2016;14:143–
152. doi: 10.1111/jth.13182
 28. Sinha RK, Wang Y, Zhao Z, Xu X, Burnier L, Gupta N, Fernández JA, Martin 
G, Kupriyanov S, Mosnier LO, Zlokovic BV, Griffin JH. PAR1 biased
signaling is required for activated protein C in vivo benefits in sepsis and
stroke. Blood. 2018;131:1163–1171. doi: 10.1182/blood-2017-10-810895
 29. Ebert J, Wilgenbus P, Teiber JF, Jurk K, Schwierczek K, Döhrmann M, Xia 
N, Li H, Spiecker L, Ruf W, Horke S. Paraoxonase-2 regulates coagulation 
activation through endothelial tissue factor. Blood. 2018;131:2161–2172. 
doi: 10.1182/blood-2017-09-807040
 30. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship
between tissue factor and cancer progression: insights from bench and
bedside. Blood. 2012;119:924–932. doi: 10.1182/blood-2011-06-317685
 31. Rak J, Milsom C, Magnus N, Yu J. Tissue factor in tumour progression. Best 
Pract Res Clin Haematol. 2009;22:71–83. doi: 10.1016/j.beha.2008.12.008
 32. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer.
J Clin Oncol. 2009;27:4834–4838. doi: 10.1200/JCO.2009.22.6324
 33. Zelaya H, Rothmeier AS, Ruf W. Tissue factor at the crossroad of coagu-
lation and cell signaling. J Thromb Haemost. 2018;16:1941–1952.
 34. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C,
Gourmelin Y, Rohde G, Martinoli JL. Laboratory assessment of rivaroxa-
ban: a review. Thromb J. 2013;11:11. doi: 10.1186/1477-9560-11-11
 35. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anti-
coagulants: pharmacokinetics in healthy subjects, specific patient popula-
tions and relevance of coagulation monitoring. Thromb J. 2013;11:10. doi: 
10.1186/1477-9560-11-10
 36. Ketha H, Mills JR. To monitor dabigatran or not: a matter of patient safety. 
Clin Chem. 2015;61:691–693. doi: 10.1373/clinchem.2014.232207
 37. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee
and Investigators. Dabigatran versus warfarin in patients with atrial fibrilla-
tion. N Engl J Med. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561
 38. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz 
MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of
dabigatran plasma concentrations and patient characteristics on the frequency 
of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY 
Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am 
Coll Cardiol. 2014;63:321–328. doi: 10.1016/j.jacc.2013.07.104
 39. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from an-
imal to human studies revisited. FASEB J. 2008;22:659–661. doi:
10.1096/fj.07-9574LSF
 40. Bode MF, Auriemma AC, Grover SP, Hisada Y, Rennie A, Bode WD, Vora 
R, Subramaniam S, Cooley B, Andrade-Gordon P, Antoniak S, Mackman
N. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a
mouse model of myocardial infarction. Thromb Res. 2018;167:128–134.
doi: 10.1016/j.thromres.2018.05.015
 41. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmaco-
kinetics, pharmacodynamics and tolerability of dabigatran etexilate, a
new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin
Pharmacol. 2007;64:292–303. doi: 10.1111/j.1365-2125.2007.02899.x
 42. Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, Katus
HA, Blessing E. Evaluation of plaque stability of advanced atheroscle-
rotic lesions in apo E-deficient mice after treatment with the oral fac-
tor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011;432080. doi:
10.1155/2011/432080
 43. Hara T, Phuong PT, Fukuda D, Yamaguchi K, Murata C, Nishimoto
S, Yagi S, Kusunose K, Yamada H, Soeki T, Wakatsuki T, Imoto I,
Shimabukuro M, Sata M. Protease-activated receptor-2 plays a crit-
ical role in vascular inflammation and atherosclerosis in apolipo-
protein E-deficient mice. Circulation. 2018;138:1706–1719. doi:
10.1161/CIRCULATIONAHA.118.033544
 44. Goto M, Miura S, Suematsu Y, Idemoto Y, Takata K, Imaizumi S,
Uehara Y, Saku K. Rivaroxaban, a factor Xa inhibitor, induces the sec-
ondary prevention of cardiovascular events after myocardial ischemia
reperfusion injury in mice. Int J Cardiol. 2016;220:602–607. doi:
10.1016/j.ijcard.2016.06.212
 45. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn
J, Hebbel RP, Monroe DM, Mackman N, Key NS, Pawlinski R.
Differential contribution of FXa and thrombin to vascular inflammation
in a mouse model of sickle cell disease. Blood. 2014;123:1747–1756. doi: 
10.1182/blood-2013-08-523936
 46. Lee IO, Kratz MT, Schirmer SH, Baumhäkel M, Böhm M. The effects of
direct thrombin inhibition with dabigatran on plaque formation and endo-
thelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 
2012;343:253–257. doi: 10.1124/jpet.112.194837
 47. Kadoglou NP, Moustardas P, Katsimpoulas M, Kapelouzou A,
Kostomitsopoulos N, Schafer K, Kostakis A, Liapis CD. The beneficial
effects of a direct thrombin inhibitor, dabigatran etexilate, on the develop-
ment and stability of atherosclerotic lesions in apolipoprotein E-deficient
mice: dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther. 
2012;26:367–374. doi: 10.1007/s10557-012-6411-3
 48. Pingel S, Tiyerili V, Mueller J, Werner N, Nickenig G, Mueller C. Thrombin 
inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. 
Arch Med Sci. 2014;10:154–160. doi: 10.5114/aoms.2014.40742
 49. Preusch MR, Ieronimakis N, Wijelath ES, Cabbage S, Ricks J, Bea F,
Reyes M, van Ryn J, Rosenfeld ME. Dabigatran etexilate retards the initi-
ation and progression of atherosclerotic lesions and inhibits the expression 
of oncostatin M in apolipoprotein E-deficient mice. Drug Des Devel Ther. 
2015;9:5203–5211. doi: 10.2147/DDDT.S86969
 50. Borissoff JI, Otten JJT, Heeneman S, et al. Genetic and pharmacological
modifications of thrombin formation in apolipoprotein e-deficient mice
determine atherosclerosis severity and atherothrombosis onset in a neutro-
phil-dependent manner. PLoS ONE. 2013;8:e55784.
 51. Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic 
S, Weiler H, Owens AP III, Mackman N, Goss A, van Ryn J, Luyendyk JP, 
Flick MJ. Thrombin promotes diet-induced obesity through fibrin-driven
inflammation. J Clin Invest. 2017;127:3152–3166. doi: 10.1172/JCI92744
 52. Kopec AK, Joshi N, Towery KL, Kassel KM, Sullivan BP, Flick MJ,
Luyendyk JP. Thrombin inhibition with dabigatran protects against
high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 
2014;351:288–297. doi: 10.1124/jpet.114.218545
 53. Antoniak S, Owens AP III, Baunacke M, et al. PAR-1 contributes
to the innate immune response during viral infection. J Clin Invest. 
2013;123:1310–1322. doi: 10.1172/JCI66125
 54. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring
M, Clemens A. Dabigatran etexilate–a novel, reversible, oral direct
thrombin inhibitor: interpretation of coagulation assays and reversal
of anticoagulant activity. Thromb Haemost. 2010;103:1116–1127. doi:
10.1160/TH09-11-0758
 55. Harenberg J, Marx S, Wehling M. Head-to-head or indirect comparisons
of the novel oral anticoagulants in atrial fibrillation: what’s next? Thromb 
Haemost. 2012;108:407–409. doi: 10.1160/TH12-07-0463
 56. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran 
on the activated partial thromboplastin time and thrombin time as deter-
mined by the Hemoclot thrombin inhibitor assay in patient plasma sam-
ples. Thromb Haemost. 2013;110:308–315. doi: 10.1160/TH13-04-0301
 57. DeFeo K, Hayes C, Chernick M, Ryn JV, Gilmour SK. Use of dabi-
gatran etexilate to reduce breast cancer progression. Cancer Biol Ther. 
2010;10:1001–1008. doi: 10.4161/cbt.10.10.13236
 58. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue
factor in the normal vessel wall and in the atherosclerotic plaque. Proc 
Natl Acad Sci USA. 1989;86:2839–2843.
 59. Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci
PM. Tissue-factor antigen and activity in human coronary atherosclerotic
plaques. Lancet. 1997;349:769–771. doi: 10.1016/S0140-6736(96)11189-2
 60. Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers
K, Govers-Riemslag JW, Hamulyák K, Hackeng TM, Daemen
MJ, ten Cate H, Spronk HM. Early atherosclerosis exhibits an
enhanced procoagulant state. Circulation. 2010;122:821–830. doi:
10.1161/CIRCULATIONAHA.109.907121
 61. Kato K, Elsayed YA, Namoto M, Nakagawa K, Sueishi K. Enhanced ex-
pression of tissue factor activity in the atherosclerotic aortas of choles-
terol-fed rabbits. Thromb Res. 1996;82:335–347.
 62. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. 
Localization and activity of tissue factor in human aortic atherosclerotic
lesions. Atherosclerosis. 1997;133:213–219.
 63. Daugherty A, Tall AR, Daemen MJAP, Falk E, Fisher EA, García-Cardeña 
G, Lusis AJ, Owens AP III, Rosenfeld ME, Virmani R; American Heart
Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; 
and Council on Basic Cardiovascular Sciences. Recommendation on de-
sign, execution, and reporting of animal atherosclerosis studies: a scien-
tific statement from the American Heart Association. Arterioscler Thromb 
Vasc Biol. 2017;37:e131–e157. doi: 10.1161/ATV.0000000000000062
 64. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient 
mice develop lesions of all phases of atherosclerosis throughout the arte-
rial tree. Arterioscler Thromb. 1994;14:133–140.
 65. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercho-
lesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 
1992;258:468–471.
 66. Davignon J. Apolipoprotein E and atherosclerosis: beyond lipid
effect. Arterioscler Thromb Vasc Biol. 2005;25:267–269. doi:
10.1161/01.ATV.0000154570.50696.2c
 67. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the
regression of atherosclerosis independently of lowering plasma cho-
lesterol levels. Arterioscler Thromb Vasc Biol. 2005;25:436–441. doi:
10.1161/01.ATV.0000152613.83243.12
 68. Getz GS, Reardon CA. Do the Apoe-/- and Ldlr-/- mice yield the same
insight on atherogenesis? Arterioscler Thromb Vasc Biol. 2016;36:1734–
1741. doi: 10.1161/ATVBAHA.116.306874
 69. Loeffen R, Spronk HM, ten Cate H. The impact of blood coagulabil-
ity on atherosclerosis and cardiovascular disease. J Thromb Haemost. 
2012;10:1207–1216. doi: 10.1111/j.1538-7836.2012.04782.x
 70. Eitzman DT, Westrick RJ, Shen Y, Bodary PF, Gu S, Manning SL, Dobies 
SL, Ginsburg D. Homozygosity for factor V Leiden leads to enhanced
thrombosis and atherosclerosis in mice. Circulation. 2005;111:1822–
1825. doi: 10.1161/01.CIR.0000160854.75779.E8
 71. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT.
Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and 
thrombosis in mice. Circulation. 2001;103:3044–3046.
 72. Tilley RE, Pedersen B, Pawlinski R, Sato Y, Erlich JH, Shen Y, Day S,
Huang Y, Eitzman DT, Boisvert WA, Curtiss LK, Fay WP, Mackman
N. Atherosclerosis in mice is not affected by a reduction in tissue fac-
tor expression. Arterioscler Thromb Vasc Biol. 2006;26:555–562. doi:
10.1161/01.ATV.0000202028.62414.3c
 73. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL.
Fibrinogen deficiency is compatible with the development of atheroscle-
rosis in mice. J Clin Invest. 1998;101:1184–1194. doi: 10.1172/JCI1461
 74. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen
deficiency reduces vascular accumulation of apolipoprotein(a) and devel-
opment of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl 
Acad Sci USA. 1998;95:12591–12595.
 75. Iwaki T, Sandoval-Cooper MJ, Brechmann M, Ploplis VA, Castellino
FJ. A fibrinogen deficiency accelerates the initiation of LDL choles-
terol-driven atherosclerosis via thrombin generation and platelet activa-
tion in genetically predisposed mice. Blood. 2006;107:3883–3891. doi:
10.1182/blood-2005-09-3780
 76. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME,
Katus H, Blessing E. Melagatran reduces advanced atherosclerotic lesion
size and may promote plaque stability in apolipoprotein E-deficient
mice. Arterioscler Thromb Vasc Biol. 2006;26:2787–2792. doi:
10.1161/01.ATV.0000246797.05781.ad
 77. Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A,
Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos
A. Noncanonical matrix metalloprotease 1-protease-activated receptor 1
signaling drives progression of atherosclerosis. Arterioscler Thromb Vasc 
Biol. 2018;38:1368–1380. doi: 10.1161/ATVBAHA.118.310967
 78. Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S,
Yagi S, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Sata
M. Rivaroxaban, a novel oral anticoagulant, attenuates atheroscle-
rotic plaque progression and destabilization in ApoE-deficient mice.
Atherosclerosis. 2015;242:639–646. doi: 10.1016/j.atherosclerosis. 
2015.03.023
 79. Jones SM, Mann A, Conrad K, Saum K, Hall DE, McKinney LM,
Robbins N, Thompson J, Peairs AD, Camerer E, Rayner KJ, Tranter M,
Mackman N, Owens AP III. PAR2 (Protease-Activated Receptor 2) defi-
ciency attenuates atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 
2018;38:1271–1282. doi: 10.1161/ATVBAHA.117.310082
 80. Raghavan S, Singh NK, Mani AM, Rao GN. Protease-activated re-
ceptor 1 inhibits cholesterol efflux and promotes atherogenesis via cul-
lin 3-mediated degradation of the ABCA1 transporter. J Biol Chem. 
2018;293:10574–10589. doi: 10.1074/jbc.RA118.003491
 81. Ruf W. Proteases, protease-activated receptors, and atheroscle-
rosis. Arterioscler Thromb Vasc Biol. 2018;38:1252–1254. doi:
10.1161/ATVBAHA.118.311139
 82. Yoon H, Radulovic M, Wu J, Blaber SI, Blaber M, Fehlings MG,
Scarisbrick IA. Kallikrein 6 signals through PAR1 and PAR2 to promote
neuron injury and exacerbate glutamate neurotoxicity. J Neurochem. 
2013;127:283–298. doi: 10.1111/jnc.12293
 83. Pawlinski R, Pawlinski R, Tencati M, et al. Protease-activated re-
ceptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 
2007;116:2298–2306.
 84. Kassel KM, Owens AP III, Rockwell CE, Sullivan BP, Wang R, Tawfik
O, Li G, Guo GL, Mackman N, Luyendyk JP. Protease-activated receptor 
1 and hematopoietic cell tissue factor are required for hepatic steatosis
in mice fed a Western diet. Am J Pathol. 2011;179:2278–2289. doi:
10.1016/j.ajpath.2011.07.015
 85. Luyendyk JP, Sullivan BP, Guo GL, Wang R. Tissue factor-deficiency and 
protease activated receptor-1-deficiency reduce inflammation elicited by
diet-induced steatohepatitis in mice. Am J Pathol. 2010;176:177–186. doi: 
10.2353/ajpath.2010.090672
 86. Khoufache K, Berri F, Nacken W, Vogel AB, Delenne M, Camerer E,
Coughlin SR, Carmeliet P, Lina B, Rimmelzwaan GF, Planz O, Ludwig
S, Riteau B. PAR1 contributes to influenza a virus pathogenicity in mice.
J Clin Invest. 2013;123:206–214. doi: 10.1172/JCI61667
87. Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ,
Chambers RC. Absence of proteinase-activated receptor-1 signal-
ing affords protection from bleomycin-induced lung inflamma-
tion and fibrosis. Am J Pathol. 2005;166:1353–1365. doi: 10.1016/ 
S0002-9440(10)62354-1
88. Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis
and atherothrombosis. Int J Biochem Cell Biol. 2010;42:1762–1766. doi: 
10.1016/j.biocel.2010.07.012
 89. Hamilton JR, Cornelissen I, Mountford JK, Coughlin SR.
Atherosclerosis proceeds independently of thrombin-induced platelet
activation in ApoE-/- mice. Atherosclerosis. 2009;205:427–432. doi:
10.1016/j.atherosclerosis.2009.01.018
90. Zuo P, Zuo Z, Zheng Y, Wang X, Zhou Q, Chen L, Ma G. Protease-
activated receptor-2 deficiency attenuates atherosclerotic lesion progres-
sion and instability in apolipoprotein E-deficient mice. Front Pharmacol. 
2017;8:647. doi: 10.3389/fphar.2017.00647
91. Antoniak S, Rojas M, Spring D, Bullard TA, Verrier ED, Blaxall BC,
Mackman N, Pawlinski R. Protease-activated receptor 2 deficiency
reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc
Biol. 2010;30:2136–2142.
92. Badeanlou L, Furlan-Freguia C, Yang G, Ruf W, Samad F. Tissue
factor-protease-activated receptor 2 signaling promotes diet-induced
obesity and adipose inflammation. Nat Med. 2011;17:1490–1497. doi:
10.1038/nm.2461
93. Wang J, Chakrabarty S, Bui Q, Ruf W, Samad F. Hematopoietic
tissue factor-protease-activated receptor 2 signaling promotes
hepatic inflammation and contributes to pathways of gluconeogen-
esis and steatosis in obese mice. Am J Pathol. 2015;185:524–535. doi:
10.1016/j.ajpath.2014.10.008
94. Oe Y, Hayashi S, Fushima T, Sato E, Kisu K, Sato H, Ito S, Takahashi N. 
Coagulation factor Xa and protease-activated receptor 2 as novel thera-
peutic targets for diabetic nephropathy. Arterioscler Thromb Vasc Biol. 
2016;36:1525–1533. doi: 10.1161/ATVBAHA.116.307883
95. Weithauser A, Bobbert P, Antoniak S, Böhm A, Rauch BH, Klingel K,
Savvatis K, Kroemer HK, Tschope C, Stroux A, Zeichhardt H, Poller
W, Mackman N, Schultheiss HP, Rauch U. Protease-activated receptor-2 
regulates the innate immune response to viral infection in a coxsacki-
evirus B3-induced myocarditis. J Am Coll Cardiol. 2013;62:1737–1745. 
doi: 10.1016/j.jacc.2013.05.076
96. Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, 
Fasano A, Vogel SN. Novel signaling interactions between proteinase-
activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal 
Immunol. 2010;3:29–39. doi: 10.1038/mi.2009.120
97. Khoufache K, LeBouder F, Morello E, Laurent F, Riffault S, Andrade-
Gordon P, Boullier S, Rousset P, Vergnolle N, Riteau B. Protective role
for protease-activated receptor-2 against influenza virus pathogenesis via 
an IFN-gamma-dependent pathway. J Immunol. 2009;182:7795–7802.
doi: 10.4049/jimmunol.0803743
98. Palazzo AJ, Jones SP, Girod WG, Anderson DC, Granger DN, Lefer DJ. 
Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient 
mice. Am J Physiol. 1998;275(6 pt 2):H2300–H2307.
99. Jong WM, Reitsma PH, ten Cate H, de Winter RJ. Modified two-
step model for studying the inflammatory response during myo-
cardial ischemia and reperfusion in mice. Comp Med. 2003;53: 
522–526.
 100. Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL, van
der Voort D, Hamulyák K, Petersen LC, Spronk HM, ten Cate H.
Active site inhibited factor VIIa attenuates myocardial ischemia/re-
perfusion injury in mice. J Thromb Haemost. 2009;7:290–298. doi:
10.1111/j.1538-7836.2008.03232.x
 101. Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL,
Hamulyák K, Ferrell G, Esmon CT, Spronk HM, ten Cate H.
Activated protein C protects against myocardial ischemia/ reperfu-
sion injury via inhibition of apoptosis and inflammation. Arterioscler 
Thromb Vasc Biol. 2009;29:1087–1092. doi: 10.1161/ATVBAHA. 
109.188656
 102. Nazir S, Gadi I, Al-Dabet MM, et al. Cytoprotective activated pro-
tein C averts Nlrp3 inflammasome-induced ischemia-reperfusion
injury via mTORC1 inhibition. Blood. 2017;130:2664–2677. doi:
10.1182/blood-2017-05-782102
 103. Kolpakov MA, Rafiq K, Guo X, Hooshdaran B, Wang T, Vlasenko L,
Bashkirova YV, Zhang X, Chen X, Iftikhar S, Libonati JR, Kunapuli SP, 
Sabri A. Protease-activated receptor 4 deficiency offers cardioprotection
after acute ischemia reperfusion injury. J Mol Cell Cardiol. 2016;90:21–
29. doi: 10.1016/j.yjmcc.2015.11.030
 104. Antoniak S, Sparkenbaugh EM, Tencati M, Rojas M, Mackman N,
Pawlinski R. Protease activated receptor-2 contributes to heart failure.
PLoS ONE. 2013;8:e81733.
 105. Li C, Balluz LS, Okoro CA, Strine TW, Lin JM, Town M, Garvin W,
Murphy W, Bartoli W, Valluru B; Centers for Disease Control and
Prevention (CDC). Surveillance of certain health behaviors and con-
ditions among states and selected local areas—behavioral risk fac-
tor surveillance system, United States, 2009. MMWR Surveill Summ. 
2011;60:1–250.
 106. Owens AP III, Passam FH, Antoniak S, et al. Monocyte tissue factor-
dependent activation of coagulation in hypercholesterolemic mice and
monkeys is inhibited by simvastatin. J Clin Invest. 2012;122:558–568.
doi: 10.1172/JCI58969
 107. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expres-
sion in the adipose tissues of obese mice. Proc Natl Acad Sci USA. 
1998;95:7591–7596.
 108. Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 
2013;122:3415–3422. doi: 10.1182/blood-2013-05-427708
 109. Flick MJ, Du X, Degen JL. Fibrin(ogen)-alpha M beta 2 interactions
regulate leukocyte function and innate immunity in vivo. Exp Biol Med
(Maywood). 2004;229:1105–1110.
 110. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonal-
coholic fatty liver disease and nonalcoholic steatohepatitis in the United
States and the rest of the world. Clin Liver Dis. 2016;20:205–214. doi:
10.1016/j.cld.2015.10.001
 111. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente 
F, Levey AS. Prevalence of chronic kidney disease in the United States.
JAMA. 2007;298:2038–2047. doi: 10.1001/jama.298.17.2038
 112. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new
approaches to an old problem. Hematology Am Soc Hematol Educ
Program. 2007;2007:91–96.
 113. Pászty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas
N, Rubin EM. Transgenic knockout mice with exclusively human sickle 
hemoglobin and sickle cell disease. Science. 1997;278:876–878.
 114. Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM.
Correction of sickle cell disease by homologous recombination in
embryonic stem cells. Blood. 2006;108:1183–1188. doi: 10.1182/ 
blood-2006-02-004812
 115. Chantrathammachart P, Mackman N, Sparkenbaugh E, Wang JG,
Parise LV, Kirchhofer D, Key NS, Pawlinski R. Tissue factor pro-
motes activation of coagulation and inflammation in a mouse model
of sickle cell disease. Blood. 2012;120:636–646. doi: 10.1182/ 
blood-2012-04-424143
 116. Sparkenbaugh EM, Chantrathammachart P, Chandarajoti K, Mackman
N, Key NS, Pawlinski R. Thrombin-independent contribution of tis-
sue factor to inflammation and cardiac hypertrophy in a mouse model
of sickle cell disease. Blood. 2016;127:1371–1373. doi: 10.1182/ 
blood-2015-11-681114
 117. Arumugam PI, Mullins ES, Shanmukhappa SK, Monia BP, Loberg
A, Shaw MA, Rizvi T, Wansapura J, Degen JL, Malik P. Genetic dim-
inution of circulating prothrombin ameliorates multiorgan patholo-
gies in sickle cell disease mice. Blood. 2015;126:1844–1855. doi:
10.1182/blood-2015-01-625707
 118. Antoniak S, Mackman N. Multiple roles of the coagulation protease
cascade during virus infection. Blood. 2014;123:2605–2613. doi:
10.1182/blood-2013-09-526277
 119. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas
J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola
virus infection with a recombinant inhibitor of factor VIIa/tissue fac-
tor: a study in rhesus monkeys. Lancet. 2003;362:1953–1958. doi:
10.1016/S0140-6736(03)15012-X
 120. Lê VB, Riteau B, Alessi MC, Couture C, Jandrot-Perrus M, Rhéaume C, 
Hamelin MÈ, Boivin G. Protease-activated receptor 1 inhibition protects 
mice against thrombin-dependent respiratory syncytial virus and human
metapneumovirus infections. Br J Pharmacol. 2018;175:388–403. doi:
10.1111/bph.14084
 121. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor
gene expression in the monocyte procoagulant response to endotoxin.
Mol Cell Biol. 1989;9:2752–2755.
 122. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert 
W, Andrade-Gordon P, Frank RD, Mackman N. Role of tissue factor and 
protease-activated receptors in a mouse model of endotoxemia. Blood. 
2004;103:1342–1347. doi: 10.1182/blood-2003-09-3051
 123. Pawlinski R, Wang JG, Owens AP III, Williams J, Antoniak S,
Tencati M, Luther T, Rowley JW, Low EN, Weyrich AS, Mackman N.
Hematopoietic and nonhematopoietic cell tissue factor activates the co-
agulation cascade in endotoxemic mice. Blood. 2010;116:806–814. doi:
10.1182/blood-2009-12-259267
 124. Camerer E, Cornelissen I, Kataoka H, Duong DN, Zheng YW, Coughlin 
SR. Roles of protease-activated receptors in a mouse model of endotox-
emia. Blood. 2006;107:3912–3921. doi: 10.1182/blood-2005-08-3130
 125. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, 
Chun J, Derian CK, Andrade-Gordon P, Rosen H, Ruf W. Dendritic cell
PAR1-S1P3 signalling couples coagulation and inflammation. Nature. 
2008;452:654–658. doi: 10.1038/nature06663
 126. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C,
Kaner RJ, Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research 
Network (IPFnet). A placebo-controlled randomized trial of warfarin in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88–
95. doi: 10.1164/rccm.201202-0314OC
 127. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ.
Changes in procoagulant and fibrinolytic gene expression during bleo-
mycin-induced lung injury in the mouse. J Clin Invest. 1995;96:1621–
1630. doi: 10.1172/JCI118201
 128. Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC,
Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, Moffatt JD, 
Laurent GJ, Derian CK, Eickelberg O, Chambers RC. Increased local
expression of coagulation factor X contributes to the fibrotic response in 
human and murine lung injury. J Clin Invest. 2009;119:2550–2563. doi:
10.1172/JCI33288
 129. Mercer PF, Johns RH, Scotton CJ, Krupiczojc MA, Königshoff M,
Howell DC, McAnulty RJ, Das A, Thorley AJ, Tetley TD, Eickelberg
O, Chambers RC. Pulmonary epithelium is a prominent source of
proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.
Am J Respir Crit Care Med. 2009;179:414–425. doi: 10.1164/rccm. 
200712-1827OC
